Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 2,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 2,000 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $54.14, for a total transaction of $108,280.00. Following the transaction, the vice president now owns 32,573 shares in the company, valued at approximately $1,763,502.22. The trade was a 5.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Patrick Lamy also recently made the following trade(s):

• On Friday, June 20th, Patrick Lamy sold 875 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.59, for a total transaction of $47,766.25.
• On Tuesday, June 10th, Patrick Lamy sold 919 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total value of $49,626.00.
• On Monday, June 2nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $50.31, for a total value of $201,240.00.
• On Thursday, May 22nd, Patrick Lamy sold 4,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.00, for a total transaction of $200,000.00.
• On Wednesday, May 7th, Patrick Lamy sold 8,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $42.49, for a total transaction of $339,920.00.

Akero Therapeutics Price Performance

AKRO stock traded down $0.17 during trading on Monday, reaching $54.03. 1,271,779 shares of the company were exchanged, compared to its average volume of 1,014,119. Akero Therapeutics, Inc. has a twelve month low of $21.02 and a twelve month high of $58.40. The company has a debt-to-equity ratio of 0.03, a current ratio of 16.80 and a quick ratio of 16.80. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of -27.71 and a beta of -0.16. The company has a 50-day moving average of $45.88 and a two-hundred day moving average of $41.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $1.91. As a group, equities analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Citigroup cut their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Bank of America upped their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Finally, HC Wainwright lifted their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $82.50.

Institutional Investors Weigh In On Akero Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Northwest & Ethical Investments L.P. bought a new position in Akero Therapeutics in the first quarter worth approximately $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of Akero Therapeutics in the fourth quarter worth approximately $41,000. PNC Financial Services Group Inc. lifted its holdings in shares of Akero Therapeutics by 30.8% in the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after purchasing an additional 390 shares in the last quarter. Sterling Capital Management LLC boosted its position in shares of Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after buying an additional 1,582 shares during the last quarter. Finally, Amalgamated Bank lifted its stake in Akero Therapeutics by 19.0% during the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company's stock valued at $104,000 after acquiring an additional 410 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.